Bring your vision of better patient health to life by partnering with Algok Bio

We leverage our team’s years of successful drug development experience to in-license or acquire promising leads and mature them into market-ready assets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris et diam quam. Sed lobortis sem a vestibulum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris et diam quam. Sed lobortis sem a vestibulum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris et diam quam. Sed lobortis sem a vestibulum

test

ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2

ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2

ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2ob title lorem ipsum dolor -2

Screenshot 2022-04-26 at 6.41 1@2x
Company value example 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam libero nunc, bibendum eget lacus id, varius accumsan erat. Fusce maximus fringilla arcu quis maximus. Sed eu ma

News

Algok Bio Acquires Global Rights to a First-In-Class Antibody Therapeutic Candidate Targeting TM4SF4 from KAERI

14 December, 2021

Discovery

Phase 1

Phase 2

Phase 3

Publications and Posters

Impact Journals
TM4SF4 overexpression in radiation-resistant lung carcinoma cells activates IGF1R via elevation of IGF1

Soo-Im Choi, Seo-Yeon Kim, Jaeha Lee, Eun-Wie Cho and In-Gyu Kim

Discovery
Preclinical
Phase 1
Phase 2
Phase 3

AGK-102

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

AGK-102

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

AGK-102

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.